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CYTOCHROME P450S AND USES THEREOF 
RELATED APPLICATIONS 
This application is a continuation of US. patent applica 
tion Ser. No. 13/199,349, ?led Aug. 26, 2011 (now issued 
US. Pat. No. 8,445,231), which is a continuation of US. 
patent application Ser. No. 12/182,000, ?led Jul. 29, 2008 
(now issued US. Pat. No. 8,263,362), which is a continuation 
of US. patent application Ser. No. 10/097,559, ?led Mar. 8, 
2002 (now issued US. Pat. No. 7,405,057), which claims the 
bene?t of US. Provisional Application Nos. 60/274,421 and 
60/275,597, ?led on Mar. 9, 2001 and Mar. 13, 2001, respec 
tively, all of which are hereby incorporated by reference. 
FIELD OF THE INVENTION 
This invention relates to cytochrome P450s and uses 
thereof. 
BACKGROUND OF THE INVENTION 
Cytochrome P450s encompass a superfamily of oxidases 
responsible for the oxidation of numerous endobiotics and 
thousands of xenobiotics. In addition, in plants, cytochrome 
P450s play important roles in wound healing, pest resistance, 
signaling, and anti-microbial and anti-fungal activity. 
Capsidiol is a bicyclic, dihydroxylated sesquiterpene pro 
duced by many Solanaceous species in response to a variety 
of environmental stimuli, including exposure to UV (Back et 
al., Plant Cell. Physiol. 389:899-904, 1998) and infection by 
microorganisms (Molot et al., Physiol. Plant Pathol. 379-389, 
1981; Stolle et al., Phytopathology 78:1193-1197, 1988; 
Keller et al., Planta. 205:467-476, 1998). It is the primary 
antibiotic or phytoalexin produced in tobacco in response to 
fungal elicitation, and it is derived from the isoprenoid path 
way via its hydrocarbon precursor, 5-epi-aristolochene (FIG. 
1). Several of the biosynthetic enzymes leading up to 5-epi 
aristolochene formation have been studied (Chappell, Annu. 
Rev. Plant Physiol. Plant Mol. Biol. 46:521-547, 1995), espe 
cially 5-epi-aristolochene synthase (BAS) (Vogeli and Chap 
pell, Plant Physiol. 88: 1291 -1296, 1988; Back and Chappell, 
Proc. Natl. Acad. Sci. USA. 93:6841-6845, 1996; Mathis et 
al., Biochemistry 36:8340-8348, 1997; Starks et al., Science 
277: 1815-1820, 1997). BAS commits carbon to sesquiter 
pene metabolism by catalyzing the cyclization of famesyl 
diphosphate (FPP) to 5-epi-aristolochene. However, until the 
present invention, the enzyme(s) responsible for the conver 
sion of 5-epi-aristolochene to capsidiol has yet to be fully 
identi?ed and characterized. 
Biochemical evidence from previous studies in tobacco 
(Whitehead et al., Phytochemistry 28:775-779, 1989) and 
green pepper (Hoshino et al., Phytochemistry 38:609-613, 
1995) have suggested that the oxidation of 5-epi-aris 
tolochene to capsidiol occurs in a two step process with one of 
the hydroxylation steps being constitutive and the other being 
mediated by an elicitor-inducible cytochrome P450 (FIG. 1). 
Because 1-deoxycapsidiol had been isolated from natural 
sources (Watson et al., Biochem. Soc. Trans. 11:589, 1983), 
Whitehead et al. (Phytochemistry 28:775-779, 1989), sur 
mised that perhaps the biosynthesis of this intermediate was 
due to pathogen induction of a corresponding hydroxylase. 
They therefore prepared synthetic 1-deoxycapsidiol and 
reported a modest conversion of this compound to capsidiol 
when fed to control or unelicited tobacco cell cultures. This 
was further supported by their observation that radiolabeled 
5-epi-aristolochene was only converted to capsidiol when fed 
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2 
to elicitor-induced cell cultures but not control cultures. 
Whitehead et al. (Phytochemistry 28:775-779, 1989) there 
fore concluded that the 3-hydroxylase, responsible for 
hydroxylation of 5-epi-aristolochene at C3 to generate 
1-deoxycapsidiol, was pathogen/elicitor inducible, while the 
1-hydroxylase, responsible for hydroxylating 1-deoxycap 
sidiol at the C1 to generate capsidiol, was constitutive. 
Hoshino et al. (Phytochemistry 38:609-613, 1995) added to 
the observations of Whitehead et al. (Phytochemistry 28:775 
779, 1989) by directly measuring 3-hydroxylase-activity in 
microsomal preparations of arachidonic acid-elicited Capsi 
cum annuum fruits and seedlings. These assays consisted of 
incubating 5-epi-aristolochene with microsome preparations 
and subsequently determining the amount of 1 -deoxycapsid 
iol generated by a combination of thin-layer chromatography 
(TLC) separations and gas chromatography (GC). Their evi 
dence demonstrated that the conversion of 5-epi-aris 
tolochene to 1-deoxycapsidiol was dependent on both 
NADPH and O2, and that 1-deoxycapsidiol accumulation in 
vitro was arrested by the P450 antagonists carbon monoxide 
(Omura and Sato, J. Biol. Chem. 239:2370-2378, 1964), 
ancymidol (Coolbaugh et al., Plant Physiol. 62:571-576, 
1978), and ketoconazole (Rademacher, Annu. Rev. Plant 
Physiol. Plant Mol. Biol. 51:501-531, 2000). 
Recent results suggest that the hydroxylation of 5-epi 
aristolochene is an important regulated step in capsidiol bio 
synthesis. In studies to evaluate the effectiveness of methyl 
jasmonate as an inducer of capsidiol biosynthesis in tobacco 
cell cultures, Mandujano-Chavez et al. (Arch. Biochem. Bio 
phys. 381 :285-294, 2000), reported that the modest accumu 
lation of this phytoalexin was accompanied by a strong induc 
tion of EAS. This result implied that steps before or after the 
sesquiterpene cyclase reaction were limiting. Using an in vivo 
assay measuring the conversion rate of radiolabeled 5-epi 
aristolochene to capsidiol, a very limited induction of the 
hydroxylase activity was observed in cells treated with 
methyl jasmonate relative to that in fungal elicitor-treated 
cells. This result pointed to the hydroxylase reactions as a 
potentially limiting step in capsidiol biosynthesis. 
SUMMARY OF THE INVENTION 
In one aspect, the invention features several isolated cyto 
chrome P450 polypeptides (such as CYP71D20, CYP71D21, 
CYP73A27, CYP73A28, and CYP92A5, and P450s having 
substantial identity to these polypeptides), as well as isolated 
nucleic acid molecules that encode these P450s. 
In related aspects, the invention features a vector (such as 
an expression vector) including an isolated nucleic acid mol 
ecule of the invention and a cell (for example, a prokaryotic 
cell, such as Agrobaclerium or E. coli, or a eukaryotic cell, 
such as a mammalian, insect, yeast, or plant cell) including 
the isolated nucleic acid molecule or vector. 
In yet another aspect, the invention features a transgenic 
plant or transgenic plant component including a nucleic acid 
molecule of the invention, wherein the nucleic acid molecule 
is expressed in the transgenic plant or the transgenic plant 
component. Preferably, the transgenic plant or transgenic 
plant component is an angiosperm (for example, a monocot or 
dicot). In preferred embodiments, the transgenic plant or 
transgenic plant component is a solanaceous, maize, rice, or 
cruciferous plant or a component thereof. The invention fur 
ther includes a seed produced by the transgenic plant or 
transgenic plant component, or progeny thereof. 
In another aspect, the invention features a method of pro 
viding an increased level of resistance against a disease 
caused by a plant pathogen in a transgenic plant. The method 
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involves: (a) producing a transgenic plant cell including the 
nucleic acid molecule of the invention integrated into the 
genome of the transgenic plant cell and positioned for expres 
sion in the plant cell; and (b) growing a transgenic plant from 
the plant cell wherein the nucleic acid molecule is expressed 
in the transgenic plant and the transgenic plant is thereby 
provided with an increased level of resistance against a dis 
ease caused by a plant pathogen. 
In another aspect, the invention features a method for pro 
ducing an altered compound, the method including the steps 
of contacting the compound with one or more of the isolated 
polypeptides disclosed herein under conditions allowing for 
the hydroxylation, oxidation, demethylation, or methylation 
of the compound and recovering the altered compound. 
In still another aspect, the invention features a hydroxylat 
ing agent including any of the isolated polypeptides disclosed 
herein. 
In yet another embodiment, the invention features an iso 
lated nucleic acid molecule that speci?cally hybridizes under 
highly stringent conditions to the complement of any one of 
the sequences described in SEQ ID N012 (CYP71D20), SEQ 
ID N014 (CYP71D21), SEQ ID N016 (CYP73A27), SEQ ID 
N018 (CYP73A28), or SEQ ID N0112 (CYP92A5), wherein 
such a nucleic acid molecule encodes a cytochrome P450 
polypeptide. 
In another aspect, the invention features a host cell express 
ing a recombinant isoprenoid synthase and a recombinant 
cytochrome P450. In preferred embodiments, the host cell 
further expresses, independently or in combination, a recom 
binant acetyltransferase, methyltransferase, or fatty acyl 
transferase. In other preferred embodiments, the host 
expresses an endogenous or recombinant cytochrome reduc 
tase. Preferably, the host cell is a yeast cell, a bacterial cell, an 
insect cell, or a plant cell. 
In a related aspect, the invention features a method for 
producing an isoprenoid compound, the method including the 
steps of: (a) culturing a cell that expresses a recombinant 
isoprenoid synthase and a recombinant cytochrome P450 
under conditions wherein the isoprenoid synthase and the 
cytochrome P450 are expressed and catalyze the formation of 
an isoprenoid compound not normally produced by the cell; 
and (b) recovering the isoprenoid compound. In preferred 
embodiments, the host cell further expresses a recombinant 
acetyltransferase, a recombinant methyltransferase, or a 
recombinant fatty acyltransferase. In other preferred embodi 
ments, the host cell expresses an endogenous or recombinant 
cytochrome reductase. Preferably, the host cell is a yeast cell, 
a bacterial cell, an insect cell, or a plant cell. 
In yet another aspect, the invention features an isoprenoid 
compound produced according to the above-mentioned 
methods. 
By “P450 polypeptide,” “cytochrome P450,” or “P450” is 
meant a polypeptide that contains a heme-binding domain 
and shows a C0 absorption spectra peak at 450 nm according 
to standard methods, for example, those described herein. 
Such P450s may also include, without limitation, hydroxy 
lase activity, dual hydroxylase activity, demethylase activity, 
or oxidase activity. Such enzymatic activities are determined 
using methods well known in the art. 
By “polypeptide” is meant any chain of amino acids, 
regardless of length or post-translational modi?cation (for 
example, glycosylation or phosphorylation). 
By “substantially identical” is meant a polypeptide or 
nucleic acid exhibiting at least 80 or 85%, preferably 90%, 
more preferably 95%, and most preferably 97%, or even 98% 
identity to a reference amino acid sequence (for example, the 
amino acid sequence shown in SEQ ID NOS: 1, 3, 5, 7 and 1 1) 
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or nucleic acid sequence (for example, the nucleic acid 
sequences shown in SEQ ID NOS12, 4, 6, 8 and 12, respec 
tively). Forpolypeptides, the length of comparison sequences 
will generally be at least 16 amino acids, preferably at least 20 
amino acids, more preferably at least 25 amino acids, and 
most preferably 35 amino acids. For nucleic acids, the length 
of comparison sequences will generally be at least 50 nucle 
otides, preferably at least 60 nucleotides, more preferably at 
least 75 nucleotides, and most preferably 110 nucleotides. 
Sequence identity is typically measured using sequence 
analysis software (for example, Sequence Analysis Software 
Package of the Genetics Computer Group, University of Wis 
consin Biotechnology Center, 1710 University Avenue, 
Madison, Wis. 53705, BLAST, or PILEUP/PRETTYBOX 
programs). Such software matches identical or similar 
sequences by assigning degrees of homology to various sub 
stitutions, deletions, and/or other modi?cations. Conserva 
tive substitutions typically include substitutions within the 
following groups: glycine, alanine; valine, isoleucine, leu 
cine; aspartic acid, glutamic acid, asparagine, glutamine; 
serine, threonine; lysine, arginine; and phenylalanine, 
tyrosine. 
By an “isolated polypeptide” is meant a P450 polypeptide 
(for example, a CYP71D20 (SEQ ID N011), CYP71D21 
(SEQ ID N013), CYP73A27 (SEQ ID N015), CYP73A28 
(SEQ ID N017), or CYP92A5 (SEQ ID N011 1) polypeptide) 
that has been separated from components that naturally 
accompany it. Typically, the polypeptide is isolated when it is 
at least 60%, by weight, free from the proteins and naturally 
occurring organic molecules with which it is naturally asso 
ciated. Preferably, the preparation is at least 75%, more pref 
erably at least 90%, and most preferably at least 99%, by 
weight, a P450 polypeptide. An isolated P450 polypeptide 
may be obtained, for example, by extraction from a natural 
source (for example, a plant cell); by expression of a recom 
binant nucleic acid encoding a P450 polypeptide; or by 
chemically synthesizing the protein. Purity can be measured 
by any appropriate method, for example, column chromatog 
raphy, polyacrylamide gel electrophoresis, or by HPLC 
analysis. 
By “derived from” or “obtained from” is meant isolated 
from or having the sequence of a naturally-occurring 
sequence (e.g., cDNA, genomic DNA, synthetic, or combi 
nation thereof). 
By “isolated nucleic acid molecule” is meant a nucleic acid 
molecule, e.g., a DNA molecule, that is free of the nucleic 
acid sequence(s) which, in the naturally-occurring genome of 
the organism from which the nucleic acid molecule of the 
invention is derived, ?ank the nucleic acid molecule. The 
term therefore includes, for example, a recombinant DNA 
that is incorporated into a vector; into an autonomously rep 
licating plasmid or virus; or into the genomic DNA of a 
prokaryote or eukaryote; or that exists as a separate molecule 
(for example, a cDNA or a genomic or cDNA fragment pro 
duced by PCR or restriction endonuclease digestion) inde 
pendent of other sequences. The term “isolated nucleic acid 
molecule” also includes a recombinant DNA which is part of 
a hybrid gene encoding additional polypeptide sequences. 
By “speci?cally hybridizes” is meant that a nucleic acid 
sequence is capable of hybridizing to a DNA sequence at least 
under low stringency conditions, and preferably under high 
stringency conditions. For example, high stringency condi 
tions may include hybridization at approximately 42° C. in 
about 50% formamide, 0.1 mg/mL sheared salmon sperm 
DNA, 1% SDS, 2><SSC, 10% Dextran sulfate, a ?rst wash at 
approximately 65° C. in about 2><SSC, 1% SDS, followed by 
a second wash at approximately 650 C. in about 0.1><SSC. 
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Alternatively high stringency conditions may include hybrid 
ization at approximately 42° C. in about 50% forrnamide, 0.1 
mg/mL sheared salmon sperm DNA, 0.5% SDS, 5><SSPE, 1>< 
Denhardt’s, followed by two washes at room temperature in 
2><SSC, 0.1% SDS, and two washes at between 55-600 C. in 
0.2><SSC, 0.1% SDS. Reducing the stringency of the hybrid 
ization conditions may involve lowering the wash tempera 
ture and/or washing at a higher concentration of salt. For 
example, low stringency conditions may include washing in 
2><SSC, 0.1% SDS at 40° C. 
By “transformed cell” is meant a cell into which (or into an 
ancestor of which) has been introduced, by means of recom 
binant DNA techniques, a DNA molecule encoding (as used 
herein) a P450 polypeptide. 
By “positioned for expression” is meant that the DNA 
molecule is positioned adjacent to a DNA sequence which 
directs transcription and translation of the sequence (i.e., 
facilitates the production of, for example, a P450 polypeptide, 
a recombinant protein, or an RNA molecule). 
By “reporter gene” is meant a gene whose expression may 
be assayed; such genes include, without limitation, beta-glu 
curonidase (GUS), luciferase, chloramphenicol transacety 
lase (CAT), green ?uorescent protein (GFP), beta-galactosi 
dase, herbicide resistant genes, and antibiotic resistance 
genes. 
By “expression control region” is meant any minimal 
sequence suf?cient to direct transcription. Included in the 
invention are promoter elements that are suf?cient to render 
promoter-dependent gene expression controllable for cell-, 
tissue-, or organ-speci?c gene expression, or elements that 
are inducible by external signals or agents (for example, 
light-, pathogen-, wound-, stress-, or hormone-inducible ele 
ments or chemical inducers such as salicylic acid (SA) or 
2,2-dichloro isonicotinic acid (INA)); such elements may be 
located in the 5' or 3' regions of the native gene or engineered 
into a transgene construct. 
By “operably linked” is meant that a gene and a regulatory 
sequence(s) are connected in such a way as to permit gene 
expression when the appropriate molecules (for example, 
transcriptional activator proteins) are bound to the regulatory 
sequence(s). 
By “plant cell” is meant any self-propagating cell bounded 
by a semi-permeable membrane and typically is one contain 
ing a plastid. Such a cell also requires a cell wall if further 
propagation is desired. Plant cell, as used herein includes, 
without limitation, algae, cyanobacteria, seeds, suspension 
cultures, embryos, meristematic regions, callus tissue, leaves, 
roots, shoots, gametophytes, sporophytes, pollen, and 
microspores. 
By “plant component” is meant a part, segment, or organ 
obtained from an intact plant or plant cell. Exemplary plant 
components include, without limitation, somatic embryos, 
leaves, stems, roots, ?owers, tendrils, fruits, scions, and root 
stocks. 
By “transgene” is meant any piece of DNA which is 
inserted by arti?ce into a cell and typically becomes part of 
the genome, for example, the nuclear or plastidic genome, of 
the organism which develops from that cell. Such a transgene 
may include a gene which is partly or entirely heterologous 
(i.e., foreign) to the transgenic organism, or may represent a 
gene homologous to an endogenous gene of the organism. 
By “transgenic” is meant any cell which includes a DNA 
sequence which is inserted by arti?ce into a cell and becomes 
part of the genome of the organism which develops from that 
cell. As used herein, the transgenic organisms are generally 
transgenic plants and the DNA (transgene) is inserted by 
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arti?ce into the nuclear or plastidic genome. A transgenic 
plant according to the invention may contain one or more 
engineered traits. 
By “pathogen” is meant an organism whose infection of 
viable plant tissue elicits a disease response in the plant tissue. 
Such pathogens include, without limitation, bacteria, myco 
plasmas, fungi, insects, nematodes, viruses, and viroids. Plant 
diseases caused by these pathogens are described in Chapters 
11-16 of Agrios, Plant Pathology, 3rd ed., Academic Press, 
Inc., New York, 1988. 
By “increased level of resistance” is meant a greater level 
of resistance to a disease-causing pathogen in a transgenic 
plant (or cell or seed thereof) of the invention than the level of 
resistance relative to a control plant (for example, a non 
transgenic plant). In preferred embodiments, the level of 
resistance in a transgenic plant of the invention is at least 20% 
(and preferably 30% or 40%) greater than the resistance of a 
control plant. In other preferred embodiments, the level of 
resistance to a disease-causing pathogen is 50% greater, 60% 
greater, and more preferably even 75% or 90% greater than a 
control plant; with up to 100% above the level of resistance as 
compared to a control plant being most preferred. The level of 
resistance is measured using conventional methods. For 
example, the level of resistance to a pathogen may be deter 
mined by comparing physical features and characteristics (for 
example, plant height and weight, or by comparing disease 
symptoms, for example, delayed lesion development, 
reduced lesion size, leaf wilting and curling, water-soaked 
spots, and discoloration of cells) of transgenic plants. 
By “puri?ed antibody” is meant antibody which is at least 
60%, by weight, free from proteins and naturally-occurring 
organic molecules with which it is naturally associated. Pref 
erably, the preparation is at least 75%, more preferably 90%, 
and most preferably at least 99%, by weight, antibody, for 
example, an acquired resistance polypeptide-speci?c anti 
body. A puri?ed P450 antibody may be obtained, for 
example, by af?nity chromatography using a recombinantly 
produced P450 polypeptide and standard techniques. 
By “speci?cally binds” is meant an antibody which recog 
nizes and binds a P450 protein but which does not substan 
tially recognize and bind other molecules in a sample, for 
example, a biological sample, which naturally includes a 
P450 protein such as CYP71D20, CYP71D21, CYP73A27, 
CYP73A28, or CYP92A5. 
Other features and advantages of the invention will be 
apparent from the following description of the preferred 
embodiments thereof, and from the claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic diagram of a proposed alternative 
pathway for the biosynthesis of capsidiol in elicitor-treated 
Nicoliana labacum cells. 5-epi-aristolochene is synthesized 
from FPP by the action of a sesquiterpene cyclase, 5-epi 
aristolochene synthase (EAS), and is subsequently hydroxy 
lated at C1 and C3 to form capsidiol. 
FIG. 2 is a graph showing an induction time course for 
sesquiterpene cyclase enzyme activity and sesquiterpene 
hydroxylase activity in cellulase-treated cell cultures. Ses 
quiterpene cyclase (5-epi-aristolochene synthase, EAS) 
enzyme activity was determined in extracts prepared from 
control (open squares) and elicitor-treated (closed squares) 
cells collected at the indicated time points. Sesquiterpene 
hydroxylase activity was determined using an indirect assay 
for control (open circles) and elicitor-treated (closed circles) 
cells. Cell cultures were incubated with [3H]-5-epi-aris 
tolochene for 3 hours ending at the indicated time points 




































